Nontaya Nakkam, Niwat Saksit, Parinya Konyoung, Warayuwadee Amornpinyo, Usanee Khunarkornsiri, Danklai Purimart, Oranuch Pattanacheewapull, Tanaporn Naewla, Pansakon Wattanachai, Kanyarat Khaeso, Pansu Chumworathayi, Wichittra Tassaneeyakul
Co-trimoxazole is mainly used as a first-line drug for treatment and prophylaxis against Pneumocystis jiroveci pneumonia. This drug, however, has been reported as the most common causative drug for severe cutaneous adverse reactions (SCARs). This study aimed to extensively elucidate the associations between genetic polymorphisms of HLA class I and genes involved in bioactivation and detoxification of co-trimoxazole on co-trimoxazole-induced SCARS in a large sample size and well-defined Thai SCARs patients. A total of 67 patients with co-trimoxazole-induced SCARs, consisting of 51 SJS/TEN patients and 16 DRESS patients, and 91 co-trimoxazole tolerant controls were enrolled in the study...
December 2022: Drug Metabolism and Pharmacokinetics